127 related articles for article (PubMed ID: 27530357)
1. Fully synthetic self-adjuvanting MUC1-fibroblast stimulating lipopeptide 1 conjugates as potential cancer vaccines.
Liu Y; Zhang W; He Q; Yu F; Song T; Liu T; Zhang Z; Zhou J; Wang PG; Zhao W
Chem Commun (Camb); 2016 Sep; 52(72):10886-9. PubMed ID: 27530357
[TBL] [Abstract][Full Text] [Related]
2. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
[TBL] [Abstract][Full Text] [Related]
3. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.
Cai H; Sun ZY; Chen MS; Zhao YF; Kunz H; Li YM
Angew Chem Int Ed Engl; 2014 Feb; 53(6):1699-703. PubMed ID: 24449389
[TBL] [Abstract][Full Text] [Related]
4. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
Gaidzik N; Westerlind U; Kunz H
Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
[TBL] [Abstract][Full Text] [Related]
6. Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.
Wilkinson BL; Day S; Malins LR; Apostolopoulos V; Payne RJ
Angew Chem Int Ed Engl; 2011 Feb; 50(7):1635-9. PubMed ID: 21308921
[No Abstract] [Full Text] [Related]
7. A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy.
Huang ZH; Shi L; Ma JW; Sun ZY; Cai H; Chen YX; Zhao YF; Li YM
J Am Chem Soc; 2012 May; 134(21):8730-3. PubMed ID: 22587010
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and immunological evaluation of self-adjuvanting MUC1-macrophage activating lipopeptide 2 conjugate vaccine candidates.
McDonald DM; Wilkinson BL; Corcilius L; Thaysen-Andersen M; Byrne SN; Payne RJ
Chem Commun (Camb); 2014 Sep; 50(71):10273-6. PubMed ID: 25056269
[TBL] [Abstract][Full Text] [Related]
9. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of a Self-Adjuvanting MUC1 Vaccine via Diselenide-Selenoester Ligation-Deselenization.
McDonald DM; Hanna CC; Ashhurst AS; Corcilius L; Byrne SN; Payne RJ
ACS Chem Biol; 2018 Dec; 13(12):3279-3285. PubMed ID: 30359529
[TBL] [Abstract][Full Text] [Related]
11. Synthetic MUC1 Antitumor Vaccine Candidates with Varied Glycosylation Pattern Bearing R/S-configured Pam3 CysSerLys4.
Shi L; Cai H; Huang ZH; Sun ZY; Chen YX; Zhao YF; Kunz H; Li YM
Chembiochem; 2016 Aug; 17(15):1412-5. PubMed ID: 27188544
[TBL] [Abstract][Full Text] [Related]
12. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.
Nuhn L; Hartmann S; Palitzsch B; Gerlitzki B; Schmitt E; Zentel R; Kunz H
Angew Chem Int Ed Engl; 2013 Sep; 52(40):10652-6. PubMed ID: 24038824
[TBL] [Abstract][Full Text] [Related]
13. First self-adjuvant multicomponent potential vaccine candidates by tethering of four or eight MUC1 antigenic immunodominant PDTRP units on a calixarene platform: synthesis and biological evaluation.
Geraci C; Consoli GM; Granata G; Galante E; Palmigiano A; Pappalardo M; Di Puma SD; Spadaro A
Bioconjug Chem; 2013 Oct; 24(10):1710-20. PubMed ID: 24041198
[TBL] [Abstract][Full Text] [Related]
14. Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein.
Cai H; Degliangeli F; Palitzsch B; Gerlitzki B; Kunz H; Schmitt E; Fiammengo R; Westerlind U
Bioorg Med Chem; 2016 Mar; 24(5):1132-5. PubMed ID: 26853835
[TBL] [Abstract][Full Text] [Related]
15. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
[TBL] [Abstract][Full Text] [Related]
16. Covalent bond or noncovalent bond: a supramolecular strategy for the construction of chemically synthesized vaccines.
Gao Y; Sun ZY; Huang ZH; Chen PG; Chen YX; Zhao YF; Li YM
Chemistry; 2014 Oct; 20(42):13541-6. PubMed ID: 25155367
[TBL] [Abstract][Full Text] [Related]
17. β-Glucan as an immune activator and a carrier in the construction of a synthetic MUC1 vaccine.
Wang H; Yang B; Wang Y; Liu F; Fernández-Tejada A; Dong S
Chem Commun (Camb); 2018 Dec; 55(2):253-256. PubMed ID: 30534737
[TBL] [Abstract][Full Text] [Related]
18. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
[TBL] [Abstract][Full Text] [Related]
19. Potentiating the immune response of MUC1-based antitumor vaccines using a peptide-based nanovector as a promising vaccine adjuvant.
Liu Y; Wang Y; Yu F; Zhang Z; Yang Z; Zhang W; Wang PG; Zhao W
Chem Commun (Camb); 2017 Aug; 53(68):9486-9489. PubMed ID: 28799590
[TBL] [Abstract][Full Text] [Related]
20. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
Li M; Yu F; Yao C; Wang PG; Liu Y; Zhao W
Org Biomol Chem; 2018 Feb; 16(6):993-999. PubMed ID: 29345713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
